A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo

Gedeon Richter

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: RGB-10; Drug: Teriparatide

Study type: Interventional

Funder types: Industry

Identifiers

NCT02223416

RGB-10-001

Details and patient eligibility

About

Pharmacokinetic properties, safety and tolerability of RGB-10 and Forsteo will be compared in healthy female volunteers.

Sex: Female

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Healthy adult female subjects
• 18-55 years of age (inclusive)
• BMI must be between 18.5 and 27 kg/m2 (inclusive)

Exclusion Criteria:

Trial design

0 participants in 2 patient groups

RGB-10

Experimental group

Treatment:

Drug: RGB-10

Forsteo

Active Comparator group

Treatment:

Drug: Teriparatide